Comparative Pharmacology
Head-to-head clinical analysis: PAXIPAM versus SERAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PAXIPAM versus SERAX.
PAXIPAM vs SERAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PAXIPAM (flurazepam) is a benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and producing CNS depression.
SERAX (oxazepam) is a benzodiazepine that modulates GABA-A receptors, enhancing the inhibitory effect of GABA, leading to anxiolytic, sedative, and anticonvulsant effects.
5-10 mg orally every 8-12 hours as needed; maximum 40 mg/day.
Oral: 5-10 mg twice daily; maximum 20 mg/day. Intravenous: 2-5 mg slow IV push, may repeat after 2 hours.
None Documented
None Documented
Terminal elimination half-life is 30-40 hours in healthy adults; prolonged in elderly and hepatic impairment.
Terminal elimination half-life is 8-15 hours (mean 12 hours) in adults; prolonged in renal impairment.
Renal excretion of unchanged drug and glucuronide metabolites accounts for 60-70%; fecal excretion accounts for 20-30%.
Primarily renal (urinary) as unchanged drug (60-80%) and metabolites (20-40%); less than 5% fecal elimination.
Category C
Category C
Benzodiazepine
Benzodiazepine